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The role of the sympathetic nervous system, stress,
and hypertension inmetabolic syndrome and obesity
remains unclear. To clarify this issue, we utilized
genetically engineeredmice showing chronic sympa-
thoexcitation and hypertension due to lack of Vav3,
a Rac1 activator. Here, we report that these animals
develop metabolic syndrome under chow diet. How-
ever, they show protection frommetabolic syndrome
and obesity under fatty diets. These effects are
elicited by a1-adrenergic- and diet-dependent meta-
bolic changes in liver and the a1/b3 adrenergic-medi-
ated stimulation of brown adipocyte thermogenesis.
These responses seem to be engaged by the local
action of noradrenaline in target tissues rather than
by long-range effects of adrenaline. By contrast,
they are not triggered by low parasympathetic drive
or the hypertensive state present in Vav3-deficient
mice. These results indicate that the sympathetic
system plays divergent roles in the etiology of meta-
bolic diseases depending on food regimen, sympa-
thoexcitation source, and disease stage.
INTRODUCTION
Metabolic syndrome (MS) encompasses a complex array of dys-
functions, such as type 2 diabetes, liver steatosis, dyslipemia,
pan-inflammatory conditions, and hypertension, often, but not
always, linked to obesity (Moller and Kaufman, 2005). This con-
dition has become pandemic in recent years due to increased
sedentary and high-calorie-diet lifestyles in both developing
and industrialized societies (Hossain et al., 2007). It is therefore
important to understand the physiological and metabolic mech-
anisms affecting the origin and progression of this complex
disease.CelOne of the main mechanisms to buffer energy surpluses
induced by high calorie intake is to engage energy-consuming
anabolic and catabolic programs in the white adipose tissue
(WAT) and brown adipose tissue (BAT), respectively. The WAT
consumes energy by synthesizing and storing triglycerides.
The BAT dissipates energy as heat using a thermogenic, mito-
chondrial-based program (Cannon and Nedergaard, 2004).
These two activities are coordinated by the sympathetic nervous
system (SNS) via the local release of noradrenaline (also known
as norepinephrine) in WAT and BAT. This catecholamine pro-
motes WAT lipolysis as well as BAT recruitment, lipolysis, and
thermogenesis (Cannon and Nedergaard, 2004; Robidoux
et al., 2004). In some conditions, the SNS can trigger further ther-
mogenesis via the generation, expansion, and stimulation of
brown-in-white (brite) adipocytes in the WAT (Robidoux et al.,
2004). The SNS also controls basal metabolic rates and other
diet-related processes (i.e., insulin secretion or glucose meta-
bolism), thus ensuring the coordinated control of energy expen-
diture at the whole organism level (Lambert et al., 2010).
Depending on the type of the physiological response involved,
the SNS can regulate the above processes by releasing
noradrenaline from local fibers or, alternatively, using the adren-
aline (also known as epinephrine) secreted by the adrenal gland
medulla (Lambert et al., 2010). The integration of metabolic
parameters and SNS activation takes place primarily in different
areas of the central nervous system that coordinate food intake
and body weight. Those regions, in turn, receive signals from tis-
sue afferents, adipose tissue-generated adipokines, thyroid hor-
mones, and metabolites (Morton et al., 2006).
In addition to the disruption of adipose tissue-dependent re-
sponses during MS and obesity, it has been postulated that
the development of some of those diseases can originate as a
consequence of sustained activation of the SNS. In favor of
this view, some epidemiological studies have shown that individ-
uals affected by sympathetic-driven chronic stress, tachycardia,
or borderline hypertension have higher tendencies to develop
MS-related diseases and obesity (Lambert et al., 2010; Mancia
et al., 2007; Pervanidou and Chrousos, 2012). Conversely,
some studies have linked obesity-induced SNS activity withl Metabolism 18, 199–211, August 6, 2013 ª2013 Elsevier Inc. 199
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hypertension and atherosclerosis (Lambert et al., 2010; Mancia
et al., 2007). However, it is worth noting the existence of quite
a few contradictory clinical reports on all of those issues; so, at
this moment, this is still an open area of debate (Lambert et al.,
2010; Mancia et al., 2007).
To dissect the role of the SNS in MS ontogeny in a genetically
clean manner, in this work we decided to use a knockout mouse
strain for Vav3, a gene that encodes a Rho guanosine diphos-
phate (GDP)/guanosine triphosphate (GTP) exchange factor
(Rho GEF) involved in the upstream activation of the Rac1 sub-
family of Rho guanosine triphosphatases (GTPases) (Movilla
and Bustelo, 1999). These animals display chronic sympathoex-
citation due to axon migration and guidance defects that disrupt
the GABAergic wiring that connects the caudal ventrolateral
medulla (CVLM) with the rostral ventrolateral medulla (RVLM)
in the brainstem. As a consequence, these animals develop
RVLM- and SNS-associated dysfunctions such as tachycardia,
tachypnea, hypertension, and other hypertension-related dys-
functions (Guyenet, 2006; Sauzeau et al., 2006, 2010a). Thus,
we believed that this mutant mouse strain could represent an
ideal tool to investigate the effect of sustained SNS hyperactivity
and the VLM itself on both diet-induced physiological responses
and the etiology of MS and obesity.
RESULTS
Vav3-Deficient Mice Develop Liver Steatosis and Type 2
Diabetes under Chow Diet Conditions
Given the general effects of the SNSon energy balance andbasal
metabolism (Lambert et al., 2010), we decided to investigate
whetherVav3/micehaddefects in anyof thoseparameters un-
der chow diet conditions.We did not find any difference between
Vav3/ and control mice in body weight (Figures S1A–S1C
available online), percentages of fat and lean mass (Figures
S1B and S1C), cumulative food intake (Figure S1D), circadian
VO2/VCO2 quotients (Figure S1E), or overall energy expenditure
(Figure S1F). These mice did show a slight reduction in loco-
motor activity during the dark period (Figure S1G). However,
such difference was not relevant when normalized according to
their specific lean mass (Figure S1G). In addition, no variations
were observed in plasma levels of thyroid-stimulating hormone,
triiodothyronine (T3), or thyroxine (T4) (Figures S1H–S1J).
Further analyses revealed that Vav3/ mice developed
hepatic steatosis, as evidenced by the abnormal large size (Fig-
ure 1A) and increased weight (Figure 1B) of livers obtained from
euthanized animals. Consistent with this, we also observed the
characteristic presence of lipid-enriched hepatocytes (Figures
1C and 1D) and high amounts of triglycerides (Figure 1E) in livers
from Vav3/ mice. The fatty liver disease became visually and
histologically detectable in 4-month-oldmice, and since then un-
derwent a progressive worsening until reaching a nonalcoholic
fatty liver or steatohepatitic state in 90% of 1-year-old mice
(Figures 1C and 1D). Alterations in liver function were indirectly
confirmed by the detection of elevated concentrations of triglyc-
erides (Figure 1F) and liver dysfunction markers such g-glutamyl
transpeptidase (GGT, Figure 1G) and bilirubin (Figure 1H) in the
plasma of Vav3/ mice. The hypertriglyceridemia coincided
with the time in which the physical and histological signs of liver200 Cell Metabolism 18, 199–211, August 6, 2013 ª2013 Elsevier Incsteatosis were detected (Figure 1F). However, GGT and bilirubin
were already upregulated in 2-month-old mice (Figures 1G and
1H), indicating that liver dysfunctions started earlier than the
physical manifestations of steatosis in Vav3/ mice.
These mice also displayed typical signs of type 2 diabetes,
including hyperglycemia (Figure 2A, compare values at time
point 0), decreased glucose tolerance (Figures 2A and 2B), and
hyperinsulinemia (Figures 2C and 2D). Impaired glucose toler-
ance was first detected in 2-month-old animals and remained
a stable parameter throughout the life of Vav3-deficient mice
(Figure 2B). The basal hyperinsulinemic state was also consis-
tently detected in 3- to 12-month-old animals (Figure 2C). This
last defect was due to both increased pancreatic secretion
(Figure 2E) and reduced clearance by the liver (Figure 2F). The
intravenous injection of insulin induced lower amounts of Akt
phosphorylation in the liver (Figure 2G) and less efficient glucose
clearance rates from circulation (Figure 2H) in Vav3/mice than
in controls, further confirming the loss of Vav3-induced type 2
diabetes in mice. Quantitative RT-PCR (qRT-PCR) analyses indi-
cated that these physiological changes correlated with progres-
sive, time-dependent changes in the expression of transcripts
associated with the development of a postreceptor insulin-resis-
tant state (Figure S2A). The first change observed was the
upregulation of the Ppargc1a messenger RNA (mRNA) in 1.5-
month-old mice (Figures S2B and S2C). This transcript encodes
Pgc1a, a cyclic AMP (cAMP)-induced transcriptional cofactor
involved in glucagon-mediated fasting responses such as gluco-
neogenesis, fatty acid oxidation, and ketogenesis. It also favors
insulin resistance by inhibiting Akt in a TRB3-dependent manner
(Figure S2A) (Fernandez-Marcos and Auwerx, 2011). mRNAs
for transcriptional factors involved in de novo lipogenesis and
fatty liver disease (Srebp1, sterol regulatory element-binding
protein 1) were first seen upregulated in 2.5-month-oldmice (Fig-
ures S2A, S2C, and S2D) (Shao and Espenshade, 2012). By
contrast, transcripts for Ppara and Insig2 became upregulated
only in 3.5-month-old mice (Figures S2A–S2D). Ppara is a tran-
scriptional factor that cooperates with Pgc1a in some signaling
responses, including the induction of insulin resistance in a
TRB3-dependent manner (Figure S2A) (Kersten et al., 2000).
Insig2 is a negative regulator of Srebp1 that is positively and
negatively regulated by Ppara and the insulin/phosphatidylinosi-
tol 3-kinase (PI3K)/Akt route, respectively (Figure S2A) (Dong
and Tang, 2010). All those mRNAs were found upregulated in
6-month-old Vav3/ mice (Figure S6). Despite this steatotic
state, these mice did not develop typical peripheral dysfunctions
associated with postreceptor insulin resistance, such as adipo-
cyte hypertrophy or obesity (Figures S1B and S2C; see also Fig-
ure 3C) (Brown and Goldstein, 2008).
To rule out the possibility that this phenotype was induced by
the hypertensive state of Vav3/ mice, we performed similar
analyses inmice deficient for a secondmember of the Vav family,
Vav2. This mutant strain shows angiotensin II-dependent hyper-
tension and high plasma catecholamine levels. However, unlike
Vav3/ mice, the upregulation of plasma catecholamines is
angiotensin II dependent in this case and, therefore, is located
downstream rather than upstream of the hypertensive condition
(Sauzeau et al., 2010b). We did not find any sign of liver steatosis
(Figures 2I and 2J), hyperinsulinemia (Figure 2K), hyperglycemia
(Figure 2L), or impaired glucose tolerance (Figure 2L) in these.
Figure 1. Vav3–/– Mice Develop Steatosis
(A and B) Representative images (A) and evolution
of weight (B) of livers isolated from chow diet-fed
mice of the indicated genotypes and ages. *p %
0.05 relative to same-age controls (n = 5). In (A)
and in the rest of the figures, all images of whole
livers were taken using the same magnification.
(C) Representative images of histological sections
obtained from livers of mice of indicated geno-
types and ages. Scale bar = 100 mm.
(D) Anatomopathology of livers from mice of indi-
cated genotypes and ages (left). The x/y ratio
represents the number of animals (x) showing a
given phenotype within the total number of ani-
mals (y) analyzed. Values diverging between con-
trol and mutant mice are shown in red. NAFL,
nonalcoholic fatty liver; NASH, nonalcoholic
steatohepatitis.
(E) Triglyceride content of livers from 4-month-old
mice of indicated genotypes. *p % 0.05 (n = 6).
WT, wild-type mice; KO, Vav3/ mice.
(F–H) Plasma concentrations of triglycerides (F),
g-glutamyl transpeptidase (GGT) (G), and bilirubin
(H) in mice of the indicated genotypes and ages.
*p% 0.05 relative to values obtained at the same
time point with controls (n = 4–5). Error bars in this
figure represent the SEM. See also Figure S1.
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direct cause of the MS present in Vav3/ mice.
The Vav3 Deficiency Protects Mice from High-Fat-Diet-
Induced Obesity
We next investigated whether the administration of a high-fat
diet (HFD) could aggravate the fatty liver disease and insulin
resistance of Vav3/ mice. To that end, we fed cohorts of
2-month-old mice with a HFD for a 10-month-long period. Unlike
wild-type animals, we observed that HFD-fed Vav3-deficient
mice gained less weight (Figures 3A and S3A), had smaller fat
deposits (Figures 3B and S3A), and did not develop white adipo-
cyte hypertrophy (Figures 3C and 3D). Against our initial expec-
tations, we also found that the HFD seemed to exert beneficial
actions on Vav3/ animals, since the abnormal increases in
the weight and triglyceride content of livers previously found in
chow diet-fed Vav3/ mice were reduced by the HFD adminis-Cell Metabolism 18, 199–21tration (Figures 3E–3H). Moreover, livers
from HFD-fed mutant mice maintained
the high abundance of the Ppargc1a
mRNA but did not show the upregulation
of Srebp1c, Ppara, or Insig2 transcripts
when compared to HFD-fed controls
(Figure 3I). Consistent with the lack of
steatosis, this tissue also showed a low
abundance of the mRNA encoding fatty
acid synthase (Fasn) (Figure 3I), an
enzyme essential for lipid biosynthesis.
HFD-fed Vav3/ mice showed glucose
tolerance (Figure 3J), insulin sensitivity
(Figure 3K), and plasma insulin levels (Fig-
ure 3L) similar to those found in chowdiet-fed wild-type mice, further indicating that the Vav3 defi-
ciency affects obesity and MS-like dysfunctions in a diet-type-
dependent manner.
Vav3-Deficient Mice Show Enhanced BAT
Thermogenesis
The resistance to HFD-induced obesity of Vav3/mice was not
due to changes in food intake (Figure S3B), circadian VO2/VCO2
quotients (Figure S3C), overall energy expenditure (Figures S3D
and S3E), or the plasma concentration of the thyroid-derived T3
(1.08 ± 0.06 versus 1.02 ± 0.08 ng/ml in controls) and T4 (3.52 ±
0.19 versus 2.77 ± 0.26 ng/ml in controls; n = 5 mice/genotype)
hormones. However, they showed increased levels of energy
expenditure per lean mass (Figure S3E, right panel) and loco-
motor activity during the light period (Figure S3F). Further
analyses indicated that they also displayed higher intrascapular
surface (Figures 4A and 4B) and rectal (37.9C ± 0.1C versus1, August 6, 2013 ª2013 Elsevier Inc. 201
Figure 2. Chow-Fed Vav3–/– Mice Develop Type 2 Diabetes
(A) Glucose tolerance test showing reduced glucose tolerance in chow diet-fed 4-month-old Vav3/mice. *p% 0.05 relative to values obtained at the same time
point with controls (n = 5).
(B) Area under the curve (a.u.c.) values for the plasma concentration of glucose in mice of indicated genotypes and ages upon an injection of glucose. **p% 0.01;
***p% 0.001 relative to same-age controls (n = 5).
(C) Plasma insulin levels in mice of indicated genotypes and ages. *p% 0.05 relative to values obtained at the same time point with controls (n = 4–6).
(D) Evolution of insulin plasma levels upon an injection of glucose in 4-month-old mice of indicated genotypes. *p% 0.05 relative to values obtained at the same
time point with controls (n = 3–4).
(E) Effect of glucose on insulin secretion (measured indirectly through the quantification of the plasma levels of the C-peptide proteolytic byproduct generated
during insulin biosynthesis). *p% 0.05 relative to values obtained at the same time point with controls (n = 4).
(F) Clearance rates of human insulin in control and Vav3 null mice. *p% 0.05 relative to values obtained at the same time point with controls (n = 3–4).
(G) Phosphorylation levels of Akt in indicated residues in the livers of mice of indicated genotypes that were either nontreated () or treated (+) with insulin. The
expression of a-tubulin (bottom panel) was used as loading control.
(legend continued on next page)
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compared to controls. This was associated to the activation of a
BAT thermogenic program, as evidenced by the consistent, age-
independent upregulation of the Ucp1 mRNA in BAT samples
from Vav3/mice (Figures 4C–4F). Ucp1 is a BAT-specific pro-
tein that uncouples oxidative phosphorylation from the respira-
tory chain, leading to energy dissipation as heat (Cannon and
Nedergaard, 2004). The increase in the abundance of this tran-
script in both 2.5- and 3.5-month-old mice took place in parallel
to the induction of Pgc1a (Figures 4E and 4F), the transcriptional
factor involved in the transcriptional activation of the Ucp1 gene
during the thermogenic response (Cannon and Nedergaard,
2004). However, the Ppargc1a mRNA was not upregulated in
the BAT of 0.5- and 1.5-month-old mice (Figures 4C and 4D),
suggesting that other transcriptional factors were in charge of
that role during those early postnatal periods. qRT-PCR ana-
lyses indicated that Kru¨ppel-like factor 15 (Klf15) was the most
likely candidate to functionally replace Pgc1a in the BAT of
young mice (Figures S4A–S4D). Although the thermogenic
response is usually associated with a decrease in fat vesicles
present in brown adipocytes and a concomitant reduction in
cell size, histological analyses revealed that the BAT from 1-
and 6-month-old Vav3/mice was composed of cells harboring
very large lipid vesicles that were more hypertrophic than those
present in wild-type BAT samples (Figure 4G). As a result, we
observed consistently lower cell densities in the BAT of Vav3/
mice than in control animals in most ages tested (Figure 4H). This
may reflect different differentiation degrees of brown adipocytes
in control and mutant mice or, alternatively, that the lipolysis
associated with the thermogenic program is compensated in
standard diet-fed Vav3/mice by the uptake of lipids from other
tissues such as the liver or WAT. This cytological pattern
changed upon HFD administration. Thus, this diet induced the
accumulation of large lipid vacuoles in brown adipocytes (Fig-
ure 4I) and a concomitant decrease in BAT cell density (Figure 4J)
in the case of wild-type mice. By contrast, it promoted a reduc-
tion in lipid stores (Figure 4I) and an increase in BAT cell density
(Figure 4J) in the case of Vav3/ mice. Taken together, these
observations indicate that the lack of obesity development in
HFD-fed Vav3/ mice is related to increased levels of both
energy consumption per lean mass and BAT thermogenesis.
This latter program is active even under standard diet and envi-
ronmental temperature conditions.
Vav3-Deficient Mice Show Enhanced White-to-Brown
Transdifferentiation
qRT-PCR analyses revealed that the Ucp1 mRNA expression
was also upregulated in WAT samples obtained from Vav3/
mice (Figures S4E–S4I). Such an increase (8- to 9-fold) was in
fact significantly higher than that seen in BAT of same animals
(2- to 3-fold) (compare Figures 4C–4F and S4G–S4I). However,(H) Evolution of the plasma concentration of glucose in 4-month-oldmice of indica
at the same time point with controls (n = 5).
(I) Liver weight of wild-type (WT) and Vav2/ (KO) mice (n = 5).
(J) Representative images of livers (upper panels) and liver histological sections
(K) Plasma insulin levels in mice of indicated genotypes (n = 5).
(L) Evolution of the plasma concentration of glucose in mice of indicated genotyp
obtained using 4-month-old mice. Error bars in this figure represent the SEM. Se
Celit developed at later times than in the case of BAT (compare Fig-
ures 4C–4F and S4E–S4I). Unlike the case of BAT, theWAT sam-
ples from Vav3/ mice also displayed the parallel upregulation
of Ucp3 transcripts (Figures S4G and S4H). The transcripts for
Pgc1a and some of its cotranscriptional partners (Ppara, Pparg)
were also elevated in WAT samples from 4.5-month-old Vav3/
mice, but not in those from younger animals (Figures S4E–S4I),
suggesting the implication of other transcriptional factors in the
activation of the Ucp1 gene in young Vav3/ mice. Since
Ucp1 gene expression is limited to brown lineage cells (Cannon
and Nedergaard, 2004), these results indicate the presence of
ectopic thermogenesis in WAT via the generation and expansion
of brite cells.
The Thermogenesis of Vav3-Deficient Mice Is
Sympathetic Dependent
To investigate if the thermogenesis found in Vav3/ mice was
sympathetic dependent, we subjected control and mutant ani-
mals to treatments with a number of adrenergic antagonists.
The administration of the SR59230A, a b3 receptor inhibitor, pro-
moted the rapid drop in the abundance of the Ucp1mRNA in the
BAT of Vav3/ mice that, under those conditions, reached
values similar to those present in untreated control mice (Fig-
ure 5A). SR59230A had no effects on the abundance of the
Ucp1 transcript in the BAT of wild-type mice (Figure 5A). The
administration of the generic b1/b2 adrenergic inhibitor propran-
olol did not have any effect in BAT Ucp1mRNA levels in Vav3/
mice (Figure 5A). Doxazosin (an a1 adrenergic receptor antago-
nist) promoted the short-term upregulation of the Ucp1 mRNA
content in the BAT of those mice (Figure 5A). In agreement
with those results, we observed that the administration of
SR59230A also eliminated the hyperthermia of Vav3/ mice,
whereas the same dose elicited no effect on the basal tempera-
ture of control animals (Figures 5B and 5C). These results
indicate that chow diet-fed Vav3/ mice activate BAT thermo-
genesis in a sympathetic-dependent manner and that such acti-
vation utilizes the classical prothermogenic noradrenaline/b3
adrenergic receptor route present in brown and brite adipocytes.
Vav3–/– Mice Show Abnormal Regulation of SNS Activity
during Both Chow and High-Fat Diet Conditions
We previously reported that the sympathoexcitation of Vav3 null
mice, measured indirectly as increased plasma levels of cate-
cholamines, is detected in newborns and remains rather stable
up to at least 1 year of age under standard chow diet conditions.
This dysfunction precedes the angiotensin II-dependent hyper-
tension and cardiovascular remodeling that takes place in these
animals (Sauzeau et al., 2006). To investigate the evolution of
SNS activity in HFD-fed animals, we periodically monitored the
plasma concentration of those two catecholamines in mice sub-
jected to a HFD since they were 2 months old. As control, weted genotypes upon an injection of insulin. *p% 0.05 relative to values obtained
(lower panels) of mice from indicated genotypes.
es during glucose tolerance tests (n = 5). All data shown in panels (I)–(L) were
e also Figure S2.
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Figure 3. Vav3–/– Mice Are Resistant to Obesity and MS under HFD Conditions
(A) Evolution of body weight in animals of the indicated genotypes subjected to HFD since they were 2 months old. *p% 0.05; **p% 0.01; ***p% 0.001 relative to
values obtained at the same time point with controls (n = 5–6).
(B) Representative images of mice at the 6-month time point of the experiment shown in (A). F, fat; L, liver.
(C and D) Representative image of epigonadal WAT (C) and average size distribution of epigonadal white adipocytes (D) from 6-month-old mice of indicated
genotypes that were kept under either chow or HFD conditions as in (A). **p% 0.01 (n = 5).
(E and F) Representative image (E) and total weight (F) of livers extracted from 6-month-old mice of indicated genotypes previously kept under high-fat (HFD) or
chow (Chow) diet conditions for 4 months. *p% 0.05; ***p% 0.001 relative to chow diet-fed controls (n = 5).
(G) Representative image of hematoxylin and eosin (H&E) (upper panels) and oil red O-stained (lower panels, to visualize lipids) liver sections from 6-month-old
mice of indicated genotypes after being maintained under HFD conditions for 4 months. Scale bar = 200 mm.
(H) Triglyceride content of livers from 6-month-oldmice of indicated genotypes after being fed under either chow or HFDconditions for 4months. *p% 0.05; **p%
0.01 relative to chow diet-fed controls or indicated experimental pairs (in brackets) (n = 5).
(legend continued on next page)
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Figure 4. Vav3–/– Mice Show Enhanced BAT
Thermogenesis
(A and B) Representative thermal images (A) and
body temperature recordings (B) of chow diet-fed
mice of indicated genotypes and ages. ***p %
0.001 relative to same-age controls (n = 4–5).
(C–F) Abundance of indicated transcripts in the
BAT of 0.5-month-old (C), 1.5-month-old (D), 2.5-
month-old (E), and 3.5-month-old (F) wild-type
and Vav3/ mice maintained under chow diet
conditions. Values obtained for each transcript in
control mice were given an arbitrary value of 1.
a.u., arbitrary units. *p% 0.05; **p% 0.01 (n = 3–4).
(G) Representative images of BAT sections from
chow diet-fed mice of indicated genotypes and
ages. Scale bar = 200 mm.
(H) Number of brown adipocytes present in inter-
capsular BAT sections from chow diet-fed mice of
the same age. *p% 0.05; **p% 0.01; ***p% 0.001
relative to same-age controls (n = 3–4).
(I) Representative images of BAT sections from
6-month-old mice of indicated genotypes after
being fed a chow diet or HFD for 4 months. Scale
bar = 200 mm.
(J) BAT cell density in animals from the experiment
in (I). **p % 0.01; ***p % 0.001 relative to chow
diet-fed controls (n = 3–4). Error bars in this figure
represent the SEM. See also Figure S4.
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pected (Sauzeau et al., 2006), Vav3/ mice displayed higher
plasma concentrations of noradrenaline (Figure 5D) and adrena-
line (Figure 5E) than controls over the course of the experimental
period under chow diet conditions. The HFD conditions had no
influence on plasma noradrenaline during the first month of(I) Abundance of indicated transcripts in the liver of HFD-fed control and mutant mice. *p% 0.05; **p% 0.0
(J and K) Plasma concentration of glucose upon the injection of either glucose (J) or insulin (K) in 6-month-old w
HFD conditions during a 4-month period. *p% 0.05; **p% 0.01; ***p% 0.001 relative to values obtained at
(L) Plasma insulin levels present in overnight fasted 6-month-old mice of indicated genotypes and diet prot
(n = 5). Error bars in this figure represent the SEM. See also Figure S3.
Cell Metabolism 18, 199–21diet change in Vav3/ mice but, since
then, promoted a progressive reduction
in the concentration of this catechol-
amine that, at the latest experimental
time point, reached levels similar to those
shown by chow diet-fed control mice
(Figure 5D). HFD-fed wild-type mice dis-
played a transient, 3-fold increase in the
plasma concentration of noradrenaline
at 1month into the diet change and, since
that time point on, maintained higher
amounts (2-fold) of plasma noradrenaline
than when kept under chow diet (Fig-
ure 5E). The HFD conditions induced a
further, although slight, increase of the
plasma concentration of adrenaline in
Vav3/ mice upon the change into HFD
(Figure 5E). However, unlike the case
of noradrenaline, the plasma levels ofadrenaline remained at high levels during the rest of the experi-
ment conducted with Vav3-deficient mice (Figure 5E). The HFD
promoted a progressive elevation of the plasma concentration
of adrenaline in wild-type mice, with a maximum peak reached
4months after the diet change (Figure 5E). These results indicate
that the sympathoexcitation of Vav3/ mice is present both in1 (n = 5).
ild-type and Vav3/mice previously subjected to
the same time points with controls (n = 5).
ocols. *p% 0.05 relative to chow diet-fed controls
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Figure 5. BAT Thermogenesis in Vav3–/–
Mice Is Sympathetic Dependent
(A) Relative abundance of the Ucp1 mRNA in the
BAT of chow diet-fed animals of indicated geno-
types that were either nontreated () or treated
with the SR59230A (SR), propranolol (Prop), and
doxazosin (Doxa) inhibitors. **p% 0.01 (n = 5).
(B and C) Representative thermogram (B) and
body temperatures (C) of chow diet-fed mice of
indicated genotypes treated with either placebo
() or SR59230A (+) for 24 hr. ***p% 0.001 (n = 4).
(D and E) Plasma concentration of noradrenaline
(D) and adrenaline (E) in chow andHFD-fedmice of
indicated genotypes and ages. **p% 0.01; ***p%
0.001 relative to same-age controls (n = 5).
(F–J) Effect of bicuculline on the plasma concen-
trations of noradrenaline (F) and adrenaline (G),
blood pressure (H), BATUcp1mRNA levels (I), and
plasma choline (J) in chow diet-fed mice of indi-
cated genotypes. In (H), animals were anes-
thetized and placed in blood pressure recording
equipment. **p % 0.01 (n = 5). Injection times
are indicated by arrows. Scale bar = 1 min. Error
bars in this figure represent the SEM. See also
Figure S5.
Cell Metabolism
A Sympathetic-Linked Metabolic Role for a Rho GEFchow diet and during early HFD periods. Furthermore, they
show that the overall noradrenergic, but not the adrenergic,
drive of these animals is inhibited upon the long-term administra-
tion of HFD.
Since the parasympathetic nervous system (PNS) plays roles
in general metabolic regulation and liver glucose metabolism
(Marino et al., 2011), we also analyzed the status of this branch
of the autonomic system in both control and mutant mice. We
observed that chow diet-fed Vav3/ mice had a lower PNS
tone, as evidenced by the lower plasma amount of choline,
one of the degradation products of acetylcholine (Figure S5A).
Consistent with this, we found that Vav3/mice also displayed
delayed PNS-dependent gastrointestinal responses when com-
pared to controls (Figures S5B and S5C). Similar results were206 Cell Metabolism 18, 199–211, August 6, 2013 ª2013 Elsevier Inc.found in Vav2/ mice (Figure S5D), sug-
gesting that the reduction of parasympa-
thetic activity per se is not inextricably
linked to the development of metabolic
defects in mice. The overall PNS activity
was reduced under HFD conditions in
control and, to a much larger extent, in
Vav3/ mice (Figure S5E). This result
rules out the possibility that the elimina-
tion of the MS-like phenotype in HFD-
fed Vav3/ mice could be due to
a restoration or exacerbation of PNS
tone. To further assess the potential
contribution of lower PNS tone in the
liver to the metabolic defects exhibited
by Vav3/ mice, we performed hepatic
vagotomies to investigate the effects
induced by the entire PNS denervation
of liver on chow diet-fed wild-type
mice. When compared to sham-oper-ated mice, vagotomized mice exhibited normal parameters for
overall autonomic activity (Figures S5F–S5H), cardiovascular
and breathing rates (Figures S5I–S5K), liver structure (Figures
S5L and S5M), plasma concentration of hepatic markers (Fig-
ures S5N–S5P), and glucose metabolism (Figures S5Q–S5S).
Thus, in the absence of sympathoexcitation, the reduction of
parasympathetic signals to the liver does not reproduce the
dysfunctions seen in chow diet-fed Vav3/ mice. Further ana-
lyses indicated that vagotomized mice did not have active
thermogenic programs in the BAT (Figure S5T) and WAT (Fig-
ure S5U), ruling out the possibility that the activation of those
processes in Vav3/ mice could be indirectly derived from
the elimination of vagally transmitted afferent signals from the
liver.
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Show Similar Upstream, Sympathetic-Dependent
Coregulation
We have previously shown that the stereotaxic administration of
a GABAA receptor antagonist (bicuculline) into the RVLM of
wild-type mice phenocopies the Vav3 gene deficiency in
terms of induction of high plasma catecholamine levels, tachyp-
nea, tachycardia, and hypertension in mice. By contrast, this
drug has a minor impact on Vav3/ mice since they have
already lost the tonic inhibitory control regulated by presynaptic
GABAergic neurons present in the RVLM (Sauzeau et al., 2010a).
During these experiments, we observed that bicuculline induced
the same aforementioned effects when administered intrave-
nously at low doses to mice. We used this strategy to investigate
whether the hyperthermia and hypertension were subjected to
similar upstream controls by the SNS in chow diet-fed Vav3/
mice. We found that bicuculline induced a sharp and rapid
elevation of plasma catecholamines (Figures 5F and 5G), blood
pressure (Figure 5H), and BAT Ucp1 mRNA levels (Figure 5I)
when administered to wild-type mice. The latter effect could
be blocked by the SR59230A b3 receptor antagonist, further
confirming that bicuculline induced the Ucp1 transcript in wild-
type brown adipocytes in a noradrenaline/b3 receptor-depen-
dent manner (Figure 5I). However, and similar to the marginal
effect on the elevation of both plasma catecholamine (Figures
5F and 5G) and blood pressure levels (Figure 5H), bicuculline
had no detectable impact on the abundance of the BAT Ucp1
transcript when injected into Vav3/ mice (Figure 5I). As a
control, the administration of noradrenaline induced similar in-
creases in blood pressure in wild-type and Vav3/ mice (Fig-
ure 5H). The administration of bicuculline had no effect on the
plasma levels of choline in both wild-type and mutant mice (Fig-
ure 5J), indicating that the short-term systemic administration of
this drug only had an effect in the sympathetic branch of the
autonomic nervous system. These results indicate that the
hypertension and BAT hyperthermia present in Vav3/ mice
are both associated to dysfunctions in the tonic control of the
SNS by inhibitory GABAergic signals.
a1 Adrenergic Receptor Antagonists Block the
Metabolic Dysfunctions Present in Chow- and HFD-fed
Vav3–/– Mice
The results presented in the previous sections did not give any
hint about the potential implication of the SNS in the liver steato-
sis and type 2 diabetes exhibited by Vav3/ mice under chow
diet conditions. To tackle this issue, we decided to investigate
the effect of the systemic administration of a1 (doxazosin) and
b1/b2 (propranolol) adrenergic receptor antagonists in chow
diet-fed Vav3/ and wild-type mice. We chose those inhibitors
because a1 and b2 adrenergic receptors play major roles in
metabolic regulation in liver, skeletal muscle, and other tissues,
including brain (Lambert et al., 2010). To that end, we started
the administration of adrenergic receptor antagonists in chow
diet-fed 1-month-old animals and evaluated the results 5months
later under the same diet conditions (Figure 6A). To get further in-
formation about the effect of adrenergic receptor inhibitors on
the metabolic phenotype of Vav3/ mice, we also decided to
monitor the effect of such treatments on animals that were fed
under HFD for the last 4 months of the experiment (Figure 6A).CelWe found that the long-term application of either doxazosin or
propranolol had no effects on the overall weight (Figure 6B)
and WAT content (data now shown) of chow diet-fed Vav3/
mice. However, doxazosin, but not propranolol, prevented the
development of hepatic steatosis in chow diet-fed mutant
mice, as demonstrated by the wild-type-like size (Figures 6C
and6D), histology (Figure 6E), and triglyceride content (Figure 6F)
of their livers (for a summary of these results, see Figure S6A).
Interestingly, these treatments differentially affected the tran-
scripts previously found upregulated in the liver of Vav3/
mice. Thus, doxazosin eliminated the upregulation of Ppargc1a,
Srebp1a, and Srebp1c mRNAs (Figure S6B), whereas pro-
pranolol only affected the expression of the Ppargc1a transcript
(Figure S6B). The overexpression of Insig2 and Ppara mRNAs
was not eliminated by any of those drugs (Figure S6B), sug-
gesting that they were not regulated by SNS signals. Consistent
with the acquisition of normal metabolic responses, we ob-
served that the long-term doxazosin treatment blocked the
development of the hyperinsulemic (Figure 6G) and the glucose
intolerance (Figure 6H) states present in Vav3/ mice (Fig-
ure S6A). Unlike in the case of the short-term experiments (Fig-
ure S5A), doxazosin also eliminated the thermogenic program
previously observed in the BAT, as demonstrated by the
reduced abundance of Ppargc1a and Ucp1 mRNAs in the BAT
of Vav3/ mice (Figures S6C and S6D). Propranolol treatments
did not eliminate any of those dysfunctions (Figures 6G, 6H, S6A,
and S6C).
Under HFD conditions, doxazosin abrogated the protective
effect of the Vav3 deficiency on weight gain (Figure 6B), WAT
expansion (Figure 6I), white adipocyte hyperplasia (Figure 6J),
obesity-induced liver steatosis (Figures 6C–6E), and obesity-
triggered glucose intolerance (Figures 6H and S6A). It also elim-
inated the thermogenic programs in the BAT (Figures 6K and
S6D) and WAT (Figure S6E) of Vav3/ mice. These results indi-
cate that the chronic stimulation of a1 adrenergic receptors con-
tributes to the development of MS in chow-fed Vav3/ mice
and, in combination with b3 adrenergic receptors, to the anti-
obesity and anti-MS effects of the Vav3 deficiency in HFD-fed
mice (Figures S6A and S6F). By contrast, b1/b2 adrenergic
receptor-dependent mechanisms did not seem to contribute to
any of the above processes, since parallel propranolol treat-
ments did not induce any detectable effect on the metabolic
phenotype of both chow and HFD-fed Vav3/ mice (Figures
S6A and S6F).
DISCUSSION
This work has revealed that chow diet-fed Vav3/mice develop
an incomplete postreceptor insulin state characterized by typical
liver and plasma MS-like pathophysiologies that, unexpectedly,
is not associated to other defects such as white adipocyte
hypertrophy and obesity (Brown and Goldstein, 2008). Interest-
ingly, these mice do not develop those dysfunctions when main-
tained under long-term HFD conditions and, in addition, show a
marked protection from the obesity and MS usually elicited by
that food regimen. Our results indicate that several SNS-
dependent processes contribute to the development of this
metabolic phenotype. The lack of increased adiposity and
obesity observed in these animals under both diet conditionsl Metabolism 18, 199–211, August 6, 2013 ª2013 Elsevier Inc. 207
Figure 6. a1 Adrenergic Receptor Antagonists Block the Metabolic Dysfunctions Present in Chow- and HFD-Fed Vav3
–/– Mice
(A) Scheme of these experiments.
(B–F) Effect of doxazosin (Doxa) and propranolol (Prop) on total body weight (B) as well as on the appearance (C), overall weight (D), histology (E), and triglyceride
content (F) of livers of Vav3/ mice fed under chow or HFD (HF) conditions. *p% 0.05; **p% 0.01; ***p% 0.001 relative to controls under the same diet type
(n = 5). Scale bar in (E) = 200 mm.
(G) Plasma levels of insulin in 6-month-old mice fasted overnight and subjected to chow diet and treatments with adrenergic receptor antagonists as above.
*p% 0.05 (n = 5).
(H) a.u.c. values of the plasma concentration of glucose in 6-month-old mice of indicated genotypes and treatments upon using a glucose tolerance test.
**p% 0.01; ***p% 0.001 relative to controls under the same diet type (n = 5).
(I) Representative images of HFD-fed 6-month-old mice of indicated genotypes and treatments.
(J and K) Histological epigonadal WAT (J) and scapular BAT (K) sections from HFD-fed 6-month-old mice of indicated genotypes and treatments. Scale bar =
200 mm. Error bars in this figure represent the SEM. See also Figure S6.
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genic programs in the BAT and, subsequently, in WAT. Notably,
these programs are activated independently of the dietary (HFD)
or environmental (i.e., cold exposure) conditions that normally
trigger them under physiological conditions. The cause of the
diet-dependent diabetes and steatosis of these animals remains
to be fully explained from a mechanistic point of view. However,
an integrated analysis of the pathophysiological and molecular
changes exhibited by these mice suggests that it may entail
both liver-autonomous (diet-independent) and nonautonomous
(diet-dependent) alterations. Consistent with the presence of
intrinsic signaling events in the liver, we have observed that the
SNS-dependent upregulation of the Ppargc1a mRNA in this tis-
sue takes place independently of the diet type and pathophysio-
logical status of Vav3/ mice (Figure S6F). By contrast, the
expression of the Srebp1, Ppara, and Insig2 mRNAs is highly
dependent on the diet type and presence of active thermogenic
programs (Figure S6F). The regulation of these transcripts is
also heterogeneous, since their expression is SNS dependent
(Srebp1) and independent (Ppara, Insig2) (Figure 6F). These re-
sults indicate that this latter expression program is controlled
by signaling events extrinsic to the liver. The WAT and BAT are
likely candidates to trigger those nonautonomous responses,
as evidenced by the correlation observed between the doxazo-
sin-mediated inactivation of thermogenic programs in those tis-
sues and the elimination of the protection offered by the Vav3
deficiency against HFD-induced obesity and MS (Figure S6A).
Given the drastic antidiabetic and steatotic effects induced by
minor variations in the activity of lipolytic and fatty acid oxidation
routes in adipocytes (Girousse et al., 2013; Waki et al., 2007), it
is possible that such influence could be mediated by diet-
dependent changes in the flux of free fatty acids and triglycer-
ides between them and the liver. Consistent with this, we have
observed significant changes in the histology and abundance
of Pargc1a and Ucp1 mRNAs in the BAT, depending on the
diet type (Figures 4 and S6D). Other possibilities include HFD-
dependent changes in adrenergic drive among different tissues
and/or the activation of neuroendocrine afferent- or efferent-
based loops affecting liver metabolic output. More work will be
required to fully understand this process.
We have shown that Vav3/ mice develop SNS-dependent
dysfunctions due to the loss of tonic GABAergic inhibitory con-
trol of the RVLM (Sauzeau et al., 2010a; Sauzeau et al., 2006).
It is possible, therefore, that the metabolic defects reported
here could have a similar etiology. The lack of feeding or thyroid
hormone alterations in Vav3/mice also argues against a direct
implication of sympathoregulatory areas of the brain associated
to food intake and energy expenditure in this phenotype (Morton
et al., 2006). However, it is worth noting that the BAT thermogen-
esis found in Vav3/ mice is at odds with the known inhibitory
effects of the RVLM in this process (Madden, 2012; Morrison,
1999). This discrepancy can be taken as evidence for the
presence of additional dysfunctions in other thermoregulatory
centers in these mice, such as the rostral raphe pallidus (rRPa)
(Morrison et al., 2008). Alternatively, it is possible that the disin-
hibited RVLM of Vav3/ mice could induce rRPa-independent
thermogenesis through the chronic stimulation of sympathetic
fibers that innervate the intra-BAT vasculature. This is in agree-
ment with observations showing that, under normothermia con-Celditions, local sympathetic activity in the BAT correlates well with
the activity level of RVLM-regulated functions such as heart rate
and blood pressure (Morrison, 1999). A similar explanation can
be used for the stimulation of WAT thermogenesis and liver
routes, since most of the catecholaminergic nerve terminals in
these tissues are adjacent to blood vessels (Robidoux et al.,
2004; Yi et al., 2010). In any case, and given the multiple sympa-
thoregulatory areas involved in metabolic regulation, we cannot
formally exclude the possibility that the Vav3 deficiency could
affect some of those areas in either RVLM-dependent or -inde-
pendent fashions. If that were the case, our bicuculline experi-
ments suggest that such a role must still be linked to the proper
wiring of inhibitory, GABAergic-dependent signals. In the same
context, is also possible that SNS-dependent metabolic defects
could be further accentuated by the parallel reduction in PNS
tone present in Vav3/ mice.
The increased levels of catecholamines in the plasma of
Vav3/ mice also raise the issue of whether their metabolic
defects are induced through sympathetic efferents (using either
direct innervations or local paracrine actions from catecholamine
spillover) and/or long-range, adrenaline-mediated signals. We
currently favor the former possibility, since Vav2/ mice show
no metabolic defects, despite displaying similar levels of plasma
catecholamines (Sauzeau et al., 2007). Likewise, knockin mice
lacking Rac1 expression exclusively in vascular smooth muscle
cells indicate that they do not develop diabetes or steatosis,
despite displaying a Vav2/ cardiovascular phenotype and
elevated, angiotensin II-induced plasma levels of catechol-
amines (S.F., M.M.-M., and X.R.B., unpublished data). We have
also observed that the chronic infusion of catecholamines in
wild-type mice for 15 days using implanted drug-delivery pumps
does not trigger the upregulation of the Ppargc1a mRNA in liver
(data not shown). Notwithstanding this evidence, it is quite
possible that a hormonal-based mechanism could participate
in other metabolic programs not explored in this work. For
example, it is known that the RVLM reacts to glycoprivation by
stimulating adrenaline secretion from theadrenal gland (Verberne
and Sartor, 2010). Further analyses of additional SNS-regulated
metabolic responses will be important to identify the spectrum
of pathophysiological defects present in these mice and the ner-
vous and hormonal mechanisms involved in triggering them.
There is a lot of debate regarding the implication of chronic
sympathoexcitation and stress in the development of MS and
obesity and whether hypertension can favor insulin resistance
and MS. There are also conflicting reports on whether the
obesity-induced SNS activity can drive or collaborate in the
development of associated diseases such as hypertension or
atherosclerosis (Lambert et al., 2010; Mancia et al., 2007;
Pervanidou and Chrousos, 2012). Solving these issues is impor-
tant to understanding whether those diseases are etiologically
intertwined or, alternatively, whether they codevelop indepen-
dently in patients due to either dietary habits or lifestyle. How-
ever, it has been rather difficult answering them at the clinical
level given the multiple ethnic, gender, and environmental fac-
tors influencing the evolution of those diseases in humans
(Lambert et al., 2010). The sympathoexcitation present in Vav
family knockout mice has given us the opportunity to address
some of those questions in a genetically and environmentally
‘‘clean’’ manner. Our results are consistent with the idea thatl Metabolism 18, 199–211, August 6, 2013 ª2013 Elsevier Inc. 209
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pathophysiological dysfunctions traditionally linked to MS. In
this context, they also suggest that treatments with doxazosin,
but not with b1/b2 blockers such as propranolol, could be bene-
ficial to eliminate MS-related dysfunctions in the case of nonob-
ese individuals with both MS and signs of high SNS activity (i.e.,
hypertension, tachycardia). Such a benefit would represent a
burden, however, in the case of obese individuals with increased
SNS activity, since doxazosin would block the protective effect
of chronic sympathoexcitation on obesity and obesity-induced
MS. By contrast, our data are not consistent with an implication
of chronic sympathoexcitation in the development of obesity
regardless of the diet type used. Our work also rules out any
direct effects of hypertension per se on insulin resistance at
the systemic level, because Vav2/ mice do not display any
overt signs of insulin resistance or steatosis, despite exhibiting
angiotensin II-dependent hypertension (Sauzeau et al., 2007).
The results obtained with wild-type mice do support the gener-
ally held idea that obesity does promote SNS activation. How-
ever, the examination of that response during a 10-month-long
period has revealed that such regulation is highly complex, since
it involves the differential and time-dependent regulation of both
sympathetic neurons and the adrenal gland medulla.
These results have unveiled the implication of a Rho GEF in
biological programs connected to the regulation of metabolic
diseases. However, our genome encodes more than 60 addi-
tional Rho GEFs (Bos et al., 2007), many of which are expressed
in tissues involved in metabolic regulation, such as the liver,
adipose tissue, muscle, or brain. It is therefore quite important
to conduct further genetic analyses with members or this
enzyme family to identify new therapeutically appealing targets
for the treatment of MS, obesity, and associated diseases.
EXPERIMENTAL PROCEDURES
Animal Studies
Vav3/ and Vav2/C57BL/10 mice (Doody et al., 2001; Sauzeau et al., 2006)
were utilized according to protocols approved by the Bioethics Committees of
the University of Salamanca, CSIC, and the University of Santiago de Compos-
tela. Mice were kept in ventilated rooms in pathogen-free facilities under
controlled temperature (23C), humidity (50%), and illumination (12 hr light/
12 hr dark cycle) conditions. After weaning, mice were fed a standard chow
global diet #2918 (6.2% fat, 3.1 kcal/g; Harlan Laboratories). When indicated,
2-month-old mice were shifted to a HFD protocol (45% fat, 4.73 kcal/g;
Research Diets). Experimental procedures involving these mice are described
in the Supplemental Experimental Procedures.
Statistics
Data were analyzed using one-way ANOVA or Student’s t test for comparison
between two unpaired groups. Values were considered significant when p%
0.05. In all figures, data values are given as mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2013.07.001.
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